SCHEMBL4492260

SCHEMBL4492260

Cc1[nH]c(C)c(-c2cnc(-c3ccc(C(F)(F)F)cc3)nc2)c(=O)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.41
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
COMT P21964 1/20 0.39
SLC11A2 P49281 1/20 0.38
TNKS O95271 1/20 0.34
TNKS2 Q9H2K2 1/20 0.34
PARP2 Q9UGN5 1/20 0.34
SCN2A Q99250 2/20 0.34
TDP2 O95551 1/20 0.34
TRPV1 Q8NER1 2/20 0.33
DAO P14920 2/20 0.33
LMNA P02545 1/20 0.33
THRB P10828 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4470810 0.90 SLC2A1 (0.39) SLC2A1NPC1ALDH1A1MAPTHTT
SCHEMBL4565033 0.86 SLC2A1 (0.43) SLC2A1COMTSLC11A2TNKSTNKS2
SCHEMBL4473339 0.84 SLC2A1 (0.41) SLC2A1SCN2ATDP2KCNH2
SCHEMBL4480629 0.81 DAO (0.44) SLC2A1RAB9ACOMTSLC11A2DAO
SCHEMBL4483751 0.81 PTGES (0.48) SLC2A1COMTSLC11A2
SCHEMBL4490726 0.80 SLC2A1 (0.61) SLC2A1DAO
SCHEMBL9268964 0.80 SLC2A1 (0.58) SLC2A1SLC11A2TNKSDAO
SCHEMBL4491220 0.78 SLC2A1 (0.43) SLC2A1
SCHEMBL4472769 0.78 KDM1A (0.45) SLC2A1LMNA
SCHEMBL4486314 0.78 SLC2A1 (0.43) SLC2A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885NPC1 2243/4885ALDH1A1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.